Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
APRI > SEC Filings for APRI > Form 8-K on 20-Mar-2013All Recent SEC Filings

Show all filings for APRICUS BIOSCIENCES, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for APRICUS BIOSCIENCES, INC.


20-Mar-2013

Change in Directors or Principal Officers, Financial Statements and Exh


Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

New Chief Executive Officer

On March 18, 2013, Apricus Biosciences, Inc. (the "Company") appointed Richard W. Pascoe as Chief Executive Officer and a Class II director of the Company.

Prior to joining us, Mr. Pascoe was President and Chief Executive officer of Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, from August 2008 through March, 2013. Prior to Somaxon, he was the Chief Operating Officer at ARIAD Pharmaceuticals, an emerging oncology company, where he led commercial operations, manufacturing, information services, program and alliance management and business development. Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc., including senior vice president of neuroscience marketing and sales and vice president positions in both international sales and marketing and hospital sales. He also held positions in the commercial groups at Medco Research, Inc. (which was acquired by King), COR Therapeutics, Inc. (where he helped lead the successful launch of Integrilin®), B. Braun Interventional and the BOC Group. Mr. Pascoe served as a commissioned officer in the United States Army following his graduation from the United States Military Academy at West Point where he received a B.S degree in Leadership.

On March 18, 2013 the Company and Mr. Pascoe entered into an Employment Agreement (the "Pascoe Agreement"), pursuant to which Mr. Pascoe will receive
(i) a base salary of $425,000, (ii) a target bonus of 50% of the base salary, to be paid in accordance with the Company's customary annual bonus program for executive officers, and (iii) an initial grant of options to purchase 900,000 shares of our common stock, with an exercise price of $2.51, based on the market price of our common stock on March 18, 2013, which options vest with respect to 25% of the shares on March 18, 2014 and with respect to the remaining 75% monthly over the subsequent three year period, so that all shares are vested on the four year anniversary of Mr. Pascoe's date of hire.

The Pascoe Agreement, provides that if Mr. Pascoe's employment ends due to an involuntary termination he would receive, (i) in a lump sum payment, 12 months of his annual base salary, (ii) any unpaid bonus for the calendar year preceding his termination, to the extent that the criteria for the bonus has been met,
(iii) the average of any bonus paid during each of the three most recent fiscal years, (iv) full acceleration and vesting of his unvested equity awards, and
(v) reimbursement for the cost of continuation of health insurance benefits provided to Mr. Pascoe immediately prior to the involuntary termination pursuant to the terms of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA") for up to 12 months. If Mr. Pascoe's employment ends due to an involuntary termination within the 12 months of a change of control, then he would receive in a lump sum payment (i) 12 months of salary equal to the greater of the salary that he was receiving immediately prior to the termination and that he was receiving immediately prior to the change of control; (ii) any unpaid bonus for the calendar year preceding his termination, to the extent that all criteria for such bonus have been met, and (iii) 100% of the average bonus paid by the Company to him for services during each of the three most recent fiscal years, (iv) full acceleration and vesting of all unvested equity awards, and (v) reimbursement for the cost of continuation of health insurance benefits provided to Mr. Pascoe immediately prior to the involuntary termination pursuant to the terms of COBRA for up to 12 months.

The forgoing summary of the Pascoe Agreement is qualified in its entirety by such agreement, which is incorporated by reference herein and attached to this Form 8-K as Exhibit 10.1.

New Employment Agreements with Executive Officers

Also on March 18, 2013, the Company entered into Amended & Restated Employment Agreements with Steve Martin and Randy Berholtz and an Employment Agreement with Edward Cox (collectively, the "Employment Agreements"). The table below shows for each executive officer the 2013 base salary, target bonus rate and number of months that each executive officer will receive severance benefits, if severance benefits are triggered. A description of severance benefits appears below the table.

--------------------------------------------------------------------------------
                                                        2013 Base           Target            Number of Months:
Name               Title                                  Salary          Bonus Rate         Severance Benefits

Steve Martin       SVP, Chief Financial Officer         $  305,000                 35 %                       12
Randy Berholtz     EVP, General Counsel & Secretary        268,060                 30 %                        9
Edward Cox         VP, Corporate Development & IR          183,000                 30 %                        6

Each Employment Agreement, provides that if applicable executive officer's employment ends due to an involuntary termination he would receive, (i) in a lump sum payment, 12, 9 or 6 months, as applicable of his annual base salary,
(ii) any unpaid bonus for the calendar year preceding his termination, to the extent that the criteria for the bonus has been met, (iii) reimbursement for the cost of continuation of health insurance benefits provided to each executive officer immediately prior to the involuntary termination pursuant to the terms of COBRA for up to 12, 9 or 6 months, as applicable, and, for Mr. Martin and Mr. Berholtz only, (i) the average of any bonus paid during each of the three most recent fiscal years, and (ii) full acceleration and vesting of his unvested equity awards. If the applicable executive officer's employment ends due to an involuntary termination within the 12 months of a change of control, then he would receive in a lump sum payment (i) 12, 9 or 6 months, as applicable, of salary equal to the greater of the salary that he was receiving immediately prior to the termination and that he was receiving immediately prior to the change of control; (ii) any unpaid bonus for the calendar year preceding his termination, to the extent that all criteria for such bonus have been met, and
(iii) 100% of the average bonus paid by the Company to him for services during each of the three most recent fiscal years, (iv) full acceleration and vesting of all unvested equity awards, and (v) reimbursement for the cost of continuation of health insurance benefits provided to Employee immediately prior to the involuntary termination pursuant to the terms of COBRA for up to 12, 9 or 6 months, as applicable.

The forgoing summary of the Employment Agreements is qualified in its entirety by such agreements, which are incorporated by reference herein and attached to this Form 8-K as Exhibits 10.2, 10.3 and 10.4.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

10.1    Employment Agreement between the Company and Richard W. Pascoe dated
        March 18, 2013.

10.2    Employment Agreement between the Company and Steve Martin dated March 18,
        2013.

10.3    Employment Agreement between the Company and Randy Berholtz dated March
        18, 2013.

10.4    Employment Agreement between the Company and Edward Cox dated March 18,
        2013.

* * *


  Add APRI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for APRI - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.